Available in 600mg and 1500mg lyophilized vials
Retail isn't the end of the funnel
Recent mechanistic and epidemiological evidence indicates that conditions such as obesity, type 2 diabetes mellitus, hypertriglyceridemia, coronary heart disease, coronary slow-flow phenomenon, and diabetic peripheral neuropathy share common pathophysiological pathways, most notably insulin resistance, chronic inflammation, lipid metabolism disturbances, and endothelial dysfunction
Gut microbiota as a promising therapeutic target for age-related sarcopenia
For example, the addition of semaglutide at a dose of 0.5 mg or 1 mg per week in patients receiving basal insulin resulted in a 1% and 1.8% decrease in HbA1c, respectively, in SUSTAIN- 5